Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 13Active not recruiting 5Not yet recruiting 2Completed 2Suspended 1Enrolling by invitation 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 1

Interventions

Specimen Handling 16Biopsy 11Magnetic Resonance Spectroscopy 10Taxes 4Bevacizumab 4Cyclophosphamide 3Cetuximab 3olaparib 2decitabine and cedazuridine drug combination 2Vincristine 2Prednisone 2Paclitaxel 2Immunoglobulin G 2Gemcitabine 2Doxorubicin 2Disulfides 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2(225)Ac-DOTA-c(RGDyK) 2zimberelimab 1zanubrutinib 1trastuzumab deruxtecan 1taletrectinib 1spartalizumab 1sotigalimab 1relatlimab 1regorafenib 1prednylidene 1neratinib 1mirdametinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Surgical Procedures, Operative × 30 days × Clear all
NCT06325683 2026-06-03

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 2 Suspended
184 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡